Q:howcanweevaluateanticoagulantsinacomprehensivewaytohelpselecttherightdrugforclinicaluse?Answer:thechoiceofanticoagulantdrugsinclinicaltreatmentshouldstrictlyfollowthedrugindications,evidenceandtreat
Q:anticoagulanttherapyisanimportantpartofcardiovasculartherapy,andeveryadvanceinthefieldofanticoagulationiscriticaltotheclinic.Thestatefoodanddrugadministrationchangedthegeneralnameofkexai®from"lowmol
Comparedtonon-cancerpatientswhounderwentsimilarsurgeryTheriskofVTEincancerpatientsis4-6timeshigherthaninnon-cancerpatientsPatientsreceivingchemotherapyhada6.5foldincreasedriskofVTETheriskofDVTincancer
hemodialysisEnoxaparinisoneofthecommonlyusedanticoagulantsinhemodialysis1longhalf-life,asingleinjectioncanmaintain4-6hSmalldoseof2canmaintaintheeffectivenessofanticoagulationdialysisTherewerenobleedin